Kodiak Sciences
Biotechnology, 1200 Page ML Rd, Palo Alto, California, 94304, United States, 51-200 Employees
Phone Number: 16*********
Who is KODIAK SCIENCES
Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bri...
Read More
-
Headquarters: 1200 Page ML Rd, Palo Alto, California, 94304, United States
-
Date Founded: 2009
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from KODIAK SCIENCES
Kodiak Sciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kodiak Sciences
Answer: Kodiak Sciences's headquarters are located at 1200 Page ML Rd, Palo Alto, California, 94304, United States
Answer: Kodiak Sciences's phone number is 16*********
Answer: Kodiak Sciences's official website is https://kodiak.com
Answer: Kodiak Sciences's revenue is $50 Million to $100 Million
Answer: Kodiak Sciences's SIC: 2834
Answer: Kodiak Sciences's NAICS: 621111
Answer: Kodiak Sciences has 51-200 employees
Answer: Kodiak Sciences is in Biotechnology
Answer: Kodiak Sciences contact info: Phone number: 16********* Website: https://kodiak.com
Answer: Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC PlatformTM uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the worlds biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenues shops, restaurants and public transportation.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month